Sixty-four patients , with impaired glucose metabolism and elevated alanine aminotransferase for at least 6 months before enrollment and NAFLD activity score at least 5 in liver biopsy , were randomized as group 1 and received metformin 1700 mg/day , group 2 received rosiglitazone 4 mg/day , and group 3 received a combination of metformin 1700 mg/day and rosiglitazone 4 mg/day for 12 months .
